Reducing PEC uncertainty in coastal zones: A case study on carbamazepine, oxcarbazepine and their metabolites

Environment International

Volumn 68, Issue , 2014, Pages 177-184

  Fenet, Hélène ^a   Arpin Pont, Lauren ^a   Vanhoutte Brunier, Alice ^a,b   Munaron, Dominique ^b   Fiandrino, Annie ^b   Martínez Bueno, Maria Jesus ^a   Boillot, Clotilde ^a   Casellas, Claude ^a   Mathieu, Olivier ^c   Gomez, Elena ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b IFREMER   (France)

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Exposure assessment; Mars 3D model; Mediterranean Sea; Pharmaceuticals; POCIS

Indexed keywords

AMIDES; ATMOSPHERIC PRESSURE; DRUG PRODUCTS; METABOLITES; METEOROLOGY; OUTFALLS; SEWAGE; SUBMARINES; THREE DIMENSIONAL;

3-D MODELING; ENVIRONMENTAL CONCENTRATION; EXPOSURE ASSESSMENT; MEDITERRANEAN COASTAL ZONE; MEDITERRANEAN SEA; POCIS; PREDICTED ENVIRONMENTAL CONCENTRATIONS; WASTEWATER TREATMENT PLANTS;

COASTAL ZONES;

CARBAMAZEPINE; DRUG METABOLITE; OXCARBAZEPINE;

ADVECTION-DIFFUSION EQUATION; COASTAL ZONE; CONCENTRATION (COMPOSITION); DRUG; EFFLUENT; METABOLITE; MODELING; POLLUTION INCIDENCE; POLLUTION MONITORING; SEWAGE OUTFALL; THREE-DIMENSIONAL MODELING; WASTE DISPOSAL; WASTE FACILITY; WASTEWATER;

ARTICLE; ATMOSPHERIC PRESSURE; COASTAL WATERS; COMPUTER MODEL; CONCENTRATION (PARAMETERS); ENVIRONMENTAL PARAMETERS; FRESHWATER ENVIRONMENT; HYDRODYNAMICS; MEASURED ENVIRONMENTAL CONCENTRATION; MEDITERRANEAN SEA; PREDICTED ENVIRONMENTAL CONCENTRATION; PRIORITY JOURNAL; SEWAGE EFFLUENT; SEWER OUTFALL; TIDE; WASTE WATER TREATMENT PLANT; WATER CONTAMINATION; WIND;

MEDITERRANEAN SEA;

EXPOSURE ASSESSMENT; MARS 3D MODEL; MEDITERRANEAN SEA; PHARMACEUTICALS; POCIS;

CARBAMAZEPINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENVIRONMENTAL MONITORING; HUMANS; MEDITERRANEAN REGION; MODELS, THEORETICAL; OCEANS AND SEAS; SEASONS; SEWAGE; TANDEM MASS SPECTROMETRY; WASTE DISPOSAL FACILITIES; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL;

EID: 84907187256     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2014.03.025     Document Type: Article

References (54)

1. Alder A.C., Schaffner C., Majewsky M., Klasmeier J., Fenner K. Fate of beta-blocker human pharmaceuticals in surface water: comparison of measured and simulated concentrations in the Glatt Valley Watershed, Switzerland. Water Res 2010, 44:936-948.
2. Anderson P.D., D'Aco V.J., Shanahan P., Chapra S.C., Buzby M.E., Cunningham V.L., et al. Screening analysis of human pharmaceutical compounds in US surface waters. Environ Sci Technol 2004, 38:838-849.
3. André G., Garreau P., Garnier V., Fraunie P. Modelled variability of the sea surface circulation in the North-western Mediterranean Sea and in the Gulf of Lions. Ocean Dyn 2005, 55:294-308.
4. André G., Garreau P., Fraunie P. Mesoscale slope current variability in the Gulf of Lions. Interpretation of in-situ measurements using a three-dimensional model. Cont Shelf Res 2009, 29:407-423.
5. Andreozzi R., Marotta R., Paxeus N. Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere 2003, 50:1319-1330.
6. Bernus I., Dickinson R., Hooper W., Eadie M. Early-stage autoinduction of carbamazepine metabolism in humans. Eur J Clin Pharmacol 1994, 47:355-360.
7. Bernus I., Hooper W., Dickinson R., Eadie M. Metabolism of carbamazepine and co-administered anticonvulsants during pregnancy. Epilepsy Res 1995, 21:65-75.
8. Bernus I., Dickinson R.G., Hooper W.D., Eadie M.J. Dose-dependent metabolism of carbamazepine in humans. Epilepsy Res 1996, 24:163-172.
9. Bernus I., Dickinson R.G., Hooper W.D., Eadie M.J. The mechanism of the carbamazepine-valproate interaction in humans. Br J Clin Pharmacol 1997, 44:21-27.
10. Blumberg A.F., Mellor G.L. A description of a three-dimensional coastal ocean circulation model. Coast Estuar Sci 1987, 4:1-16.
11. Cho D.-Y., Ogburn E.T., Jones D., Desta Z. Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob Agents Chemother 2011, 55:1504-1509.
12. Clara M., Strenn B., Kreuzinger N. Carbamazepine as a possible anthropogenic marker in the aquatic environment: investigations on the behaviour of carbamazepine in wastewater treatment and during groundwater infiltration. Water Res 2004, 38:947-954.
13. Coetsier C.M., Spinelli S., Lin L., Roig B., Touraud E. Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs?. Environ Int 2009, 35:787-792.
14. Cunningham V.L., Perino C., D'Aco V.J., Hartmann A., Bechter R. Human health risk assessment of carbamazepine in surface waters of North America and Europe. Regul Toxicol Pharmacol 2010, 56:343-351.
15. Daughton C.G., Ruhoy I.S. The afterlife of drugs and the role of pharmecovigilance. Drug Saf 2008, 31:1069-1082.
16. Dickinson R., Hooper W., Dunstan P., Eadie M. 1st-dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 1989, 37:69-74.
17. Duffa C., Dufois F., Coudray S. An operational model to simulate post-accidental radionuclide transfers in Toulon marine area: preliminary development. Ocean Dyn 2011, 61:1811-1821.
18. EMEA Note for guidance on environmental risk assessment of medicinal products for human use, CMPC/SWP/4447/draft 2006, The European Agency for the Evaluation of Medicinal Products (EMEA), London.
19. Faigle J., Feldmann K. Pharmacokinetic data of carbamazepine and its major metabolites in man. Epileptic Seizure-Behaviour- Pain 1976, 159-165. W.Birkmayer, London.
20. Feijtel T., Boeije G., Matthies M., Young A., Morris G., Gandolfi C., et al. Development of a geography-referenced regional exposure assessment tool for European rivers-great-er contribution to great-er #1. Chemosphere 1997, 34:2351-2373.
21. Garreau P., Garnier V., Schaeffer A. Eddy resolving modelling of the Gulf of Lions and Catalan Sea. Ocean Dyn 2011, 61:991-1003.
22. Hannah R., D'Aco V.J., Anderson P.D., Buzby M.E., Caldwell D.J., Cunningham V.L., et al. Exposure assessment of 17 alpha-ethinylestradiol in waters of the United States and Europe. Environ Toxicol Chem 2009, 28:2725-2732.
23. Jelic A., Gros M., Ginebreda A., Cespedes-Sanchez R., Ventura F., Petrovic M., et al. Occurrence, partition and removal of pharmaceuticals in sewage water and sludge during wastewater treatment. Water Res 2011, 45:1165-1176.
24. Kalis M.M., Huff N.A. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001, 23:680-700.
25. Kassahun K., Mattiuz E., Nyhart E., Obermeyer B., Gillespie T., Murphy A., et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997, 25:81-93.
26. Lazure P., Dumas F. An external-internal mode coupling for a 3D hydrodynamical model for applications at regional scale (MARS). Adv Water Resour 2008, 31:233-250.
27. Leclercq M., Mathieu O., Gomez E., Casellas C., Fenet H., Hillaire-Buys D. Presence and fate of carbamazepine, oxcarbazepine, and seven of their metabolites at wastewater treatment plants. Arch Environ Contam Toxicol 2009, 56:408-415.
28. Leredde Y., Denamiel C., Brambilla E., Lauer-Leredde C., Bouchette F., Marsaleix P. Hydrodynamics in the gulf of Aigues-Mortes, NW Mediterranean sea: in situ and modelling data. Cont Shelf Res 2007, 27:2389-2406.
29. Lertratanangkoon K., Horning M. Metabolism of carbamazepine. Drug Metab Dispos 1982, 10:1-10.
30. Li H., Helm P.A., Metcalfe C.D. Sampling in the Great Lakes for pharmaceuticals, personal care products, and endocrine-disrupting substances using the passive polar organic chemical integrative sampler. Environ Chem 2010, 29:751-762.
31. MacLeod S.L., McClure E.L., Wong C.S. Laboratory calibration and field deployment of the Polar organic chemical integrative sampler for pharmaceuticals and personal care products in wastewater and surface water. Environ Toxicol Chem 2007, 26:2517-2529.
32. Martínez Bueno M.J., Boillot C., Fenet H., Casellas C., Gomez E. Fast and easy extraction combined with high resolution-mass spectrometry for residue analysis of two anticonvulsants and their transformation products in marine mussels. J Chromatogr A 2013, 1305:27-34.
33. Martínez Bueno M.J., Herrera S., Munaron D., Boillot C., Fenet H., Chiron S., et al. Passive sampling as a tool for monitoring pharmaceuticals and its metabolites in marine environment at trace levels: urban/industrial impact assessment. Water Res 2014, [submitted for publication].
34. Matsuo H., Sakamoto H., Arizono K., Shinohara R. Behavior of pharmaceuticals in waste water treatment plant in Japan. Bull Environ Contam Toxicol 2011, 87:31-35.
35. Miao X.S., Metcalfe C.D. Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry. Anal Chem 2003, 75:3731-3738.
36. Munaron D., Tapie N., Budzinski H., Andral B., Gonzalez J.L. Pharmaceuticals, alkylphenols and pesticides in Mediterranean coastal waters: results from a pilot survey using passive samplers. Estuar Coast Shelf Sci 2012, 114:953-968.
37. Mutlib A.E., Chen H., Nemeth G.A., Markwalder J.A., Seitz S.P., Gan L.S., et al. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 1999, 27:1319-1333.
38. Nicolle A., Garreau P., Liorzou B. Modelling for anchovy recruitment studies in the Gulf of Lions (Western Mediterranean Sea). Ocean Dyn 2009, 59:953-968.
39. Oosterhuis M., Sacher F., ter Laak T.L. Prediction of concentration levels of metformin and other high consumption pharmaceuticals in wastewater and regional surface water based on sales data. Sci Total Environ 2013, 442:380-388.
40. Pairaud I.L., Gatti J., Bensoussan N., Verney R., Garreau P. Hydrology and circulation in a coastal area off Marseille: validation of a nested 3D model with observations. J Mar Syst 2011, 88:20-33.
41. Pienimaki P., Lampela E., Hakkola J., Arvela P., Raunio H., Vahakangas K. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 1997, 38:309-316.
42. Roig B. Pharmaceuticals in the environment-current knowledge and need assessment to reduce presence and impact 2010, IWA, London, UK.
43. Rubio A., Taillandier V., Garreau P. Reconstruction of the Mediterranean northern current variability and associated cross-shelf transport in the Gulf of Lions from satellite-tracked drifters and model outputs. J Mar Syst 2009, 78:S63-S78.
44. Santos N.A.G., Medina W.S.G., Martins N.M., Carvalho Rodrigues M.A., Curti C., Santos A.C. Involvement of oxidative stress in the hepatotoxicity induced by aromatic antiepileptic drugs. Toxicol in Vitro 2008, 22:1820-1824.
45. Schütz H., Feldmann K., Faigle J., Kriemler H., Winkler T. The metabolism of oxcarbazepine-C-14 in man. Xenobiotica 1986, 16:769-778.
46. Specht U., Elsner H., May T.W., Schimichowski B., Thorbecke R. Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behav 2003, 4:487-495.
47. Ternes T., Kreckel P., Mueller J. Behaviour and occurrence of estrogens in municipal sewage treatment plants-II. Aerobic batch experiments with activated sludge. Sci Total Environ 1999, 225:91-99.
48. TGD Technical Guidance Document in support of Commission Directive 93/67/EEC on risk assessment of new notified chemicals and Commission Regulation (EC) No.1488/94 on risk assessment of existing chemicals (1996) 2003, Office for Official Publications of the European Communities, Luxembourg.
49. Togola A., Budzinski H. Development of polar organic integrative samplers for analysis of pharmaceuticals in aquatic systems. Anal Chem 2007, 79:6734-6741.
50. Vidal-Dorsch D.E., Bay S.M., Maruya K., Snyder S.A., Trenholm R.A., Vanderford B.J. Contaminants of emerging concern in municipal wastewater effluents and marine receiving water. Environ Toxicol Chem 2012, 31:2674-2682.
51. Vieno N.M., Tuhkanen T., Kronberg L. Analysis of neutral and basic pharmaceuticals in sewage treatment plants and in recipient rivers using solid phase extraction and liquid chromatography-tandem mass spectrometry detection. J Chromatogr A 2006, 1134:101-111.
52. Wad N., Guenat C., Kramer G. Carbamazepine: detection of another metabolite in serum, 9-hydroxymethyl-10-carbamoyl acridan. Ther Drug Monit 1997, 19:314-317.
53. Wille K., Noppe H., Verheyden K., Vanden Bussche J., De Wulf E., Van Caeter P., et al. Validation and application of an LC-MS/MS method for the simultaneous quantification of 13 pharmaceuticals in seawater. Anal Bioanal Chem 2010, 397:1797-1808.
54. Zhang Y., Geissen S.-U. Prediction of carbamazepine in sewage treatment plant effluents and its implications for control strategies of pharmaceutical aquatic contamination. Chemosphere 2010, 80:1345-1352.